GlassScriptPhysician profile
Abhijeet Kashyap
NPI 1710299615
$2,335.59
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57.42 · 2023: $1,491 · 2024: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.46 | 2023-2024 | |
| Boston Scientific Corporation | $319.31 | 2022-2024 | Captivator II |
| Celgene Corporation | $203.95 | 2023-2024 | Zeposia |
| Genzyme Corporation | $174.17 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.85 | 2023 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $155.36 | 2023-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $135.98 | 2023-2024 | Stelara |
| Pfizer INC. | $131.75 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $61.92 | 2023-2024 | Dupixent |
| Fresenius Kabi USA, LLC | $58.28 | 2023-2024 | Idacio |
| Ferring Pharmaceuticals INC. | $45.14 | 2023 | Rebyota |
| Qol Medical, LLC | $45.11 | 2023 | Sucraid |
| Organon LLC | $32.91 | 2023-2024 | Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $27.42 | 2023 | Linzess |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $25.60 | 2023 | Fujifilm |
| Braintree Laboratories, INC. | $25.40 | 2023 | Sutab |
| Ardelyx, INC. | $17.18 | 2023 | Ibsrela |
| Gilead Sciences, INC. | $13.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhijeet Kashyap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.